Luis Vitores Valcarcel

Luis Vitores Valcarcel

Auto-generated profile, based on publicly available information

Luis Vitores Valcarcel

Biomedical Engineering and Sciences Department, Tecnun School of Engineering, University of Navarra, San Sebastian, Spain

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 February 2019 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
LHLaurent Heirendt
Laurent Heirendt
SASylvain Arreckx
Sylvain Arreckx
TPThomas Pfau
Thomas Pfau
SMSebastián N. Mendoza
Sebastián N. Mendoza
ARAnne Richelle
Anne Richelle
RFRonan MT Fleming
Ronan MT Fleming

3 July 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CSCristina Segovia
Cristina Segovia
EJEdurne San José
Edurne San José
EMEster Munera-Maravilla
Ester Munera-Maravilla
MMMónica Martínez-Fernández
Mónica Martínez-Fernández
LGLeire Garate
Leire Garate
JESÚS M ParamioJESÚS M Paramio
JESÚS M Paramio

17 February 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
ACArantxa Carrasco-Leon
Arantxa Carrasco-Leon
TETeresa Ezponda
Teresa Ezponda
CMCem Meydan
Cem Meydan
LVLuis V. Valcárcel
Luis V. Valcárcel
RORaquel Ordoñez
Raquel Ordoñez
XAXabier Agirre
Xabier Agirre
Multiple myeloma (MM) is an incurable disease, whose clinical heterogeneity makes its management challenging, highlighting the need for biological features to guide improved therapies. Deregulation of specific long non-coding RNAs (lncRNAs) has been shown in MM, nevertheless, the complete lncRNA transcriptome has not yet been elucidated. In this work, we identified 40,511 novel lncRNAs in MM samples. lncRNAs accounted for 82% of the MM transcriptome and were more heterogeneously expressed than coding genes. A total of 10,351 overexpressed and 9,535 downregulated lncRNAs were identified in MM patients when compared with normal bone-marrow plasma cells. Transcriptional dynamics study of lncRNAs in the context of normal B-cell maturation revealed 989 lncRNAs with exclusive expression in MM, among which 89 showed de novo epigenomic activation. Knockdown studies on one of these lncRNAs, SMILO (specific myeloma intergenic long non-coding RNA), resulted in reduced proliferation and induction of apoptosis of MM cells, and activation of the interferon pathway. We also showed that the expression of lncRNAs, together with clinical and genetic risk alterations, stratified MM patients into several progression-free survival and overall survival groups. In summary, our global analysis of the lncRNAs transcriptome reveals the presence of specific lncRNAs associated with the biological and clinical behavior of the disease.

20 July 2018 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
IAIñigo Apaolaza
Iñigo Apaolaza
LVLuis Vitores Valcarcel
Luis Vitores Valcarcel
FPFrancisco J Planes
Francisco J Planes
The identification of minimal gene knockout strategies to engineer metabolic systems constitutes one of the most relevant applications of the COnstraint-Based Reconstruction and Analysis (COBRA) framework. In the last years, the minimal cut sets (MCSs) approach has emerged as a promising tool to carry out this task. However, MCSs define reaction knockout strategies, which are not necessarily transformed into feasible strategies at the gene level. We present a more general, easy-to-use and efficient computational implementation of a previously published algorithm to calculate MCSs to the gene level (gMCSs). Our tool was compared with existing methods in order to calculate essential genes and synthetic lethals in metabolic networks of different complexity, showing a significant reduction in model size and computation time. gMCS is publicly and freely available under GNU license in the COBRA toolbox (https://github.com/opencobra/cobratoolbox/tree/master/src/analysis/gMCS). Supplementary data are available at Bioinformatics online.

28 March 2019 in Bioinformatics
Verified
Journal Article
Closed access
LVLuis V Valcárcel
Luis V Valcárcel
VTVerónica Torrano
Verónica Torrano
LTLuis Tobalina
Luis Tobalina
ACArkaitz Carracedo
Arkaitz Carracedo
FPFrancisco J Planes
Francisco J Planes
Motivation: The development of computational tools exploiting -omics data and high-quality genome-scale metabolic networks for the identification of novel drug targets is a relevant topic in Systems Medicine. Metabolic Transformation Algorithm (MTA) is one of these tools, which aims to identify targets that transform a disease metabolic state back into a healthy state, with potential application in any disease where a clear metabolic alteration is observed. Results: Here, we present a robust extension to MTA (rMTA), which additionally incorporates a worst-case scenario analysis and minimization of metabolic adjustment to evaluate the beneficial effect of gene knockouts. We show that rMTA complements MTA in the different datasets analyzed (gene knockout perturbations in different organisms, Alzheimer’s disease and prostate cancer), bringing a more accurate tool for predicting therapeutic targets. Availability and implementation: rMTA is freely available on The Cobra Toolbox: https://opencobra.github.io/cobratoolbox/latest/. Supplementary information: Supplementary data are available at Bioinformatics online.

10 May 2021 in Leukemia
Verified
Journal Article
Open access
PDF file
LVLuis V. Valcárcel
Luis V. Valcárcel
AAAne Amundarain
Ane Amundarain
MKMarta Kulis
Marta Kulis
SCStella Charalampopoulou
Stella Charalampopoulou
AMAri Melnick
Ari Melnick
FPFelipe Prosper
Felipe Prosper
Clinical and genetic risk factors are currently used in multiple myeloma (MM) to stratify patients and to design specific therapies. However, these systems do not capture the heterogeneity of the disease supporting the development of new prognostic factors. In this study, we identified active promoters and alternative active promoters in 6 different B cell subpopulations, including bone-marrow plasma cells, and 32 MM patient samples, using RNA-seq data. We find that expression initiated at both regular and alternative promoters was specific of each B cell subpopulation or MM plasma cells, showing a remarkable level of consistency with chromatin-based promoter definition. Interestingly, using 595 MM patient samples from the CoMMpass dataset, we observed that the expression derived from some alternative promoters was associated with lower progression-free and overall survival in MM patients independently of genetic alterations. Altogether, our results define cancer-specific alternative active promoters as new transcriptomic features that can provide a new avenue for prognostic stratification possibilities in patients with MM.